Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events

The increasing rate of late-onset hypogonadism has led to an exceptional growth in the use of testosterone therapy (TTh). Even though TTh has been used for more than 70 years, there has been an emerging controversy in the past several years re-garding its safety due to a suggested increased risk of...

Full description

Bibliographic Details
Main Authors: Jonathan Clavell-Hernández, Run Wang
Format: Article
Language:English
Published: Korean Society for Sexual Medicine and Andrology 2018-05-01
Series:The World Journal of Men's Health
Subjects:
Online Access:https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-92.pdf
id doaj-f7994467d3ef43578109967a37b895cb
record_format Article
spelling doaj-f7994467d3ef43578109967a37b895cb2020-11-24T22:05:05ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902018-05-013629210210.5534/wjmh.17050Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular EventsJonathan Clavell-Hernández0Run Wang1University of Texas Health Science CenterUniversity of Texas Health Science CenterThe increasing rate of late-onset hypogonadism has led to an exceptional growth in the use of testosterone therapy (TTh). Even though TTh has been used for more than 70 years, there has been an emerging controversy in the past several years re-garding its safety due to a suggested increased risk of cardiovascular (CV) disease among its users. Given the growing preva-lence of testosterone deficiency in our population and the increased use of TTh, the goal of this review is to present the histo-ry and emerging evidence in regards to this controversy. CV safety concerns are mostly based on a few studies and trials that have been noted to have multiple flaws and limitations. However, the most recent data has found no association between TTh and the development of CV disease. Nevertheless, until this controversy is clarified with larger clinical trials, health-care professionals should continue to inform their patients about the possible CV risk when prescribing TTh products to patients.https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-92.pdfCardiovascular diseasesHypogonadismTestosterone
collection DOAJ
language English
format Article
sources DOAJ
author Jonathan Clavell-Hernández
Run Wang
spellingShingle Jonathan Clavell-Hernández
Run Wang
Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
The World Journal of Men's Health
Cardiovascular diseases
Hypogonadism
Testosterone
author_facet Jonathan Clavell-Hernández
Run Wang
author_sort Jonathan Clavell-Hernández
title Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
title_short Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
title_full Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
title_fullStr Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
title_full_unstemmed Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
title_sort emerging evidences in the long standing controversy regarding testosterone replacement therapy and cardiovascular events
publisher Korean Society for Sexual Medicine and Andrology
series The World Journal of Men's Health
issn 2287-4208
2287-4690
publishDate 2018-05-01
description The increasing rate of late-onset hypogonadism has led to an exceptional growth in the use of testosterone therapy (TTh). Even though TTh has been used for more than 70 years, there has been an emerging controversy in the past several years re-garding its safety due to a suggested increased risk of cardiovascular (CV) disease among its users. Given the growing preva-lence of testosterone deficiency in our population and the increased use of TTh, the goal of this review is to present the histo-ry and emerging evidence in regards to this controversy. CV safety concerns are mostly based on a few studies and trials that have been noted to have multiple flaws and limitations. However, the most recent data has found no association between TTh and the development of CV disease. Nevertheless, until this controversy is clarified with larger clinical trials, health-care professionals should continue to inform their patients about the possible CV risk when prescribing TTh products to patients.
topic Cardiovascular diseases
Hypogonadism
Testosterone
url https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-92.pdf
work_keys_str_mv AT jonathanclavellhernandez emergingevidencesinthelongstandingcontroversyregardingtestosteronereplacementtherapyandcardiovascularevents
AT runwang emergingevidencesinthelongstandingcontroversyregardingtestosteronereplacementtherapyandcardiovascularevents
_version_ 1725827471719268352